Caldwell & Orkin’s Allergan plc AGN Stock Holding History

Caldwell & Orkin’s Portfolio AGN Stock Details AGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-10,300	Closed	-$2.46M	–	98
2017 Q1	$2.46M	Buy	+10,300	New	+$2.4M	1.37%	25

Other funds holding AGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Caldwell & Orkin's AGN Position: Q2 2017 in Review

Caldwell & Orkin sold out of Allergan plc (AGN) in Q2 2017, closing a stake of 10,300 shares — an estimated $2.46M sold.

Caldwell & Orkin first reported a position in AGN in Q1 2017 and held it in 1 quarter. The position peaked at $2.46M in Q1 2017. 1,115 funds tracked by Wall St. Rank hold AGN as of Q2 2017.

Caldwell & Orkin reported no remaining Allergan plc position as of Q2 2017 after selling out during the quarter.
Caldwell & Orkin sold 10,300 Allergan plc shares in Q2 2017, an estimated $2.46M.
Caldwell & Orkin first reported a position in Allergan plc in Q1 2017 and held it in 1 quarter.
Caldwell & Orkin's Allergan plc position peaked at $2.46M in Q1 2017.
1,115 funds tracked by Wall St. Rank held Allergan plc as of Q2 2017.

Based on Caldwell & Orkin's 13F filing for Q2 2017, filed 10 Aug 2017.